155 related articles for article (PubMed ID: 37952021)
1. Neoadjuvant Therapy for Duodenal and Ampullary Adenocarcinoma: A Systematic Review.
Zhang C; Lizalek JM; Dougherty C; Westmark DM; Klute KA; Reames BN
Ann Surg Oncol; 2024 Feb; 31(2):792-803. PubMed ID: 37952021
[TBL] [Abstract][Full Text] [Related]
2. Incidence and comparative outcomes of periampullary cancer: A population-based analysis demonstrating improved outcomes and increased use of adjuvant therapy from 2004 to 2012.
Hester CA; Dogeas E; Augustine MM; Mansour JC; Polanco PM; Porembka MR; Wang SC; Zeh HJ; Yopp AC
J Surg Oncol; 2019 Mar; 119(3):303-317. PubMed ID: 30561818
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant Therapy Versus Upfront Resection for Nonpancreatic Periampullary Adenocarcinoma.
Adam MA; Glencer A; AlMasri S; Winters S; Bahary N; Singhi A; Lee KK; Paniccia A; Zureikat AH
Ann Surg Oncol; 2023 Jan; 30(1):165-174. PubMed ID: 35925536
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant therapy versus upfront surgery for early-stage left-sided pancreatic adenocarcinoma: A propensity-matched analysis from a national cohort of distal pancreatectomies.
Nassour I; Adam MA; Kowalsky S; Al Masri S; Bahary N; Singhi AD; Lee K; Zureikat A; Paniccia A
J Surg Oncol; 2021 Jan; 123(1):245-251. PubMed ID: 33103242
[TBL] [Abstract][Full Text] [Related]
5. The benefits of neoadjuvant therapy for patients with resectable pancreatic cancer: an updated systematic review and meta-analysis.
Yang B; Chen K; Liu W; Long D; Wang Y; Liu X; Ma Y; Tian X; Yang Y
Clin Exp Med; 2023 Nov; 23(7):3159-3169. PubMed ID: 37310659
[TBL] [Abstract][Full Text] [Related]
6. Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention-to-treat analysis.
Sugimoto M; Takahashi N; Farnell MB; Smyrk TC; Truty MJ; Nagorney DM; Smoot RL; Chari ST; Carter RE; Kendrick ML
J Surg Oncol; 2019 Nov; 120(6):976-984. PubMed ID: 31452208
[TBL] [Abstract][Full Text] [Related]
7. Multi-agent neoadjuvant chemotherapy improves survival in early-stage pancreatic cancer: A National Cancer Database analysis.
Deng A; Wang C; Cohen SJ; Winter JM; Posey J; Yeo C; Basu Mallick A
Eur J Cancer; 2021 Apr; 147():17-28. PubMed ID: 33607382
[TBL] [Abstract][Full Text] [Related]
8. Pathologic Response to Preoperative Therapy as a Novel Prognosticator for Ampullary and Duodenal Adenocarcinoma.
Yamashita S; Overman MJ; Wang H; Zhao J; Okuno M; Goumard C; Tzeng CW; Kim M; Fleming JB; Vauthey JN; Katz MH; Lee JE; Conrad C
Ann Surg Oncol; 2017 Dec; 24(13):3954-3963. PubMed ID: 28980211
[TBL] [Abstract][Full Text] [Related]
9. Significance of neoadjuvant therapy for borderline resectable pancreatic cancer: a multicenter retrospective study.
Kurahara H; Shinchi H; Ohtsuka T; Miyasaka Y; Matsunaga T; Noshiro H; Adachi T; Eguchi S; Imamura N; Nanashima A; Sakamoto K; Nagano H; Ohta M; Inomata M; Chikamoto A; Baba H; Watanabe Y; Nishihara K; Yasunaga M; Okuda K; Natsugoe S; Nakamura M
Langenbecks Arch Surg; 2019 Mar; 404(2):167-174. PubMed ID: 30649607
[TBL] [Abstract][Full Text] [Related]
10. Upfront surgery vs. neoadjuvant therapy for resectable pancreatic cancer: a narrative review of available evidence.
Ratnayake CBB; Roberts KJ; Pandanaboyana S
Chin Clin Oncol; 2022 Feb; 11(1):2. PubMed ID: 35184565
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Adjuvant Chemotherapy Survival Outcomes Among Patients With Surgically Resected Pancreatic Carcinoma With Node-Negative Disease After Neoadjuvant Therapy.
Hammad AY; Hodges JC; AlMasri S; Paniccia A; Lee KK; Bahary N; Singhi AD; Ellsworth SG; Aldakkak M; Evans DB; Tsai S; Zureikat A
JAMA Surg; 2023 Jan; 158(1):55-62. PubMed ID: 36416848
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant therapy vs. upfront surgery for resectable pancreatic cancer: An update on a systematic review and meta-analysis.
Xu Y; Chen Y; Han F; Wu J; Zhang Y
Biosci Trends; 2022 Jan; 15(6):365-373. PubMed ID: 34759120
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant Therapy Followed by Resection Versus Upfront Resection for Resectable Pancreatic Cancer: A Propensity Score Matched Analysis.
Mokdad AA; Minter RM; Zhu H; Augustine MM; Porembka MR; Wang SC; Yopp AC; Mansour JC; Choti MA; Polanco PM
J Clin Oncol; 2017 Feb; 35(5):515-522. PubMed ID: 27621388
[TBL] [Abstract][Full Text] [Related]
14. Comparative Effectiveness of Neoadjuvant Therapy and Upfront Resection for Patients with Resectable Pancreatic Adenocarcinoma: An Instrumental Variable Analysis.
da Costa WL; Tran Cao HS; Sheetz KH; Gu X; Norton EC; Massarweh NN
Ann Surg Oncol; 2021 Jun; 28(6):3186-3195. PubMed ID: 33174146
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant treatment for borderline resectable pancreatic adenocarcinoma is associated with higher R0 rate compared to upfront surgery.
Terlizzi M; Buscail E; Boussari O; Adgié S; Leduc N; Terrebonne E; Smith D; Blanc JF; Lapuyade B; Laurent C; Chiche L; Belleannée G; Le Malicot K; Trouette R; Pouypoudat C; Vendrely V
Acta Oncol; 2021 Sep; 60(9):1114-1121. PubMed ID: 34197269
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant therapy for pancreatic cancer.
Gugenheim J; Crovetto A; Petrucciani N
Updates Surg; 2022 Feb; 74(1):35-42. PubMed ID: 34628591
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant treatment of pancreatic adenocarcinoma: a systematic review and meta-analysis of 5520 patients.
Dhir M; Malhotra GK; Sohal DPS; Hein NA; Smith LM; O'Reilly EM; Bahary N; Are C
World J Surg Oncol; 2017 Oct; 15(1):183. PubMed ID: 29017581
[TBL] [Abstract][Full Text] [Related]
18. Feasibility and safety of distal pancreatectomy with en bloc celiac axis resection (DP-CAR) combined with neoadjuvant therapy for borderline resectable and unresectable pancreatic body/tail cancer.
Yoshitomi H; Sakai N; Kagawa S; Takano S; Ueda A; Kato A; Furukawa K; Takayashiki T; Kuboki S; Miyzaki M; Ohtsuka M
Langenbecks Arch Surg; 2019 Jun; 404(4):451-458. PubMed ID: 30868241
[TBL] [Abstract][Full Text] [Related]
19. Association Between Pancreatic Fistula and Long-term Survival in the Era of Neoadjuvant Chemotherapy.
Hank T; Sandini M; Ferrone CR; Rodrigues C; Weniger M; Qadan M; Warshaw AL; Lillemoe KD; Fernández-Del Castillo C
JAMA Surg; 2019 Oct; 154(10):943-951. PubMed ID: 31411659
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant therapy versus upfront surgery in resectable pancreatic cancer according to intention-to-treat and per-protocol analysis: A systematic review and meta-analysis.
Lee YS; Lee JC; Yang SY; Kim J; Hwang JH
Sci Rep; 2019 Oct; 9(1):15662. PubMed ID: 31666626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
